

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

**ELECTION OF THE MEANS OF RECEIPT AND
THE LANGUAGE OF CORPORATE COMMUNICATIONS**

INTRODUCTION

With a view to increasing efficiency, saving costs and protecting the environment, the arrangements described below have been made by the Company pursuant to Rules 2.07A and 2.07B of the Listing Rules and the Articles of Association to ascertain Shareholders' choice of the means of receipt (in electronic form on the website of the Company at www.sisram-medical.com, where they will continue to be published in both English and Chinese, or in printed form) and, if Shareholders elect to receive Corporate Communications in printed form, the language (in English only, in Chinese only, or in both English and Chinese) of future Corporate Communications.

PROPOSED ARRANGEMENTS

In accordance with Rules 2.07A and 2.07B of the Listing Rules and the Articles of Association, the following arrangements have been made by the Company:

1. A letter of request (the “**First Letter**”) dated April 26, 2018 together with a reply form with a mailing label attached for posting within Hong Kong (the “**Reply Form**”), in both English and Chinese, have been sent by the Company to the Shareholders to enable them to elect any one of the following options for receipt of the Corporate Communications:
 - (a) to read all future Corporate Communications published on the Company’s website at www.sisram-medical.com (the “**Website Version**”) instead of receiving printed copies, and to receive the Company’s printed notification of the publication of Corporate Communications on the website of the Company; or
 - (b) to receive the printed English version of all future Corporate Communications only; or
 - (c) to receive the printed Chinese version of all future Corporate Communications only; or
 - (d) to receive both the printed English and Chinese versions of all future Corporate Communications.

The First Letter explains that if the Company does not receive the duly completed Reply Form or receives a response indicating the objection from the Shareholder by May 28, 2018, such Shareholder will be deemed to have agreed to receiving the Website Version only instead of receiving printed copies of all future Corporate Communications. A notification of the publication of the Corporate Communications will be sent to such Shareholder by post when the relevant Corporate Communications are published on the Company's website.

2. If a Shareholder has elected in a Reply Form to receive Corporate Communications in printed form, the Company will send Corporate Communications to the Shareholder in the language or languages selected by the Shareholder unless and until the Shareholder notifies the Company c/o the Hong Kong Share Registrar by reasonable prior notice in writing or by email to sisram.ecom@computershare.com.hk that the Shareholder wishes to receive future Corporate Communications in the other or both language(s) in printed form or the Website Version of future Corporate Communications.
3. If a Shareholder has elected in a Reply Form to receive the Website Version of Corporate Communications, or is deemed (because the Shareholder has not sent a Reply Form) to have agreed to receive the Website Version of Corporate Communications, the Company will notify the Shareholder by post when each Corporate Communication is published on the Company's website. This notification will be sent to the address of the Shareholder which appears on the Company's register of members maintained by the Hong Kong Share Registrar.
4. When each Corporate Communication is sent by the Company in printed form to a Shareholder in accordance with the arrangements described in paragraph 2 above, a letter (the "**Second Letter**") and a change request form (the "**Change Request Form**") with a mailing label attached for posting within Hong Kong will be attached to or printed in the relevant Corporate Communication. The Second Letter and Change Request Form will be in English and Chinese. By completing and returning the Change Request Form to the Company c/o the Hong Kong Share Registrar or by email to sisram.ecom@computershare.com.hk, the Shareholder may elect (i) to receive the Website Version of future Corporate Communications or (ii) to change the language in which the Shareholder receives future Corporate Communications in printed form.
5. Shareholders may also at any time by reasonable notice in writing to the Company (c/o the Hong Kong Share Registrar or by email to sisram.ecom@computershare.com.hk) elect (i) to receive future Corporate Communications in printed form instead of the Website Version (or the Website Version instead of in printed form) and/or (ii) to change the language in which they receive Corporate Communications in printed form. If any Shareholder who has elected (or is deemed to have agreed) to receive the Website Version of Corporate Communications for any reason has difficulty in obtaining access to the Website Version of a Corporate Communication, the Company will upon request by the Shareholder send the Corporate Communication to the Shareholder in printed form free of charge.

6. All Corporate Communications will continue to be available on the Company's website at www.sisram-medical.com in both English and Chinese and in accessible format. Electronic copies of all Corporate Communications in both English and Chinese will also be filed with the Stock Exchange on the same day as that on which they are made available to Shareholders (or on such other day as may be required by the Stock Exchange or in order to comply with to the Listing Rules) and will be available on the website of the Stock Exchange at www.hkexnews.hk.
7. The Company is providing a hotline service (Tel: (852) 2862 8688) available during business hours (9:00 a.m. to 6:00 p.m., Monday to Friday, excluding Hong Kong public holidays) to enable Shareholders to make enquiries about the arrangements described above.
8. The First Letter and the Second Letter will indicate that Corporate Communications in both English and Chinese will be available from the Company and the Hong Kong Share Registrar upon request and on the respective websites of the Company and the Stock Exchange, and that the hotline service is being provided as described above.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

" Articles of Association"	the articles of association of the Company currently in force
"Company"	Sisram Medical Ltd, a company incorporated in Israel with limited liability, the shares of which are listed on the Main Board of the Stock Exchange
"Corporate Communications"	any documents issued or to be issued by the Company for the information or action of holders of any of the Company's securities or the investing public, including but not limited to but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form
"Hong Kong Share Registrar"	Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong

“ Listing Rules ”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“ Shareholder(s) ”	holder(s) of ordinary share(s) of the Company
“ Stock Exchange ”	The Stock Exchange of Hong Kong Limited

On Behalf of the Board
Sisram Medical Ltd
Yi LIU
Chairman

Hong Kong, April 26, 2018

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Jianping HUA as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Yang YANG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.